Revvity (RVTY) has been drawing attention after a period of mixed share performance. The stock is roughly flat year to date, higher over the past month, and lower over the past three months.

Revvity’s recent 11.51% 30 day share price return contrasts with a 1.39% decline year to date. The 1 year total shareholder return of 6.27% sits against weaker 3 and 5 year outcomes, suggesting short term momentum against a softer longer term record.

If you are weighing Revvity’s recent move and want to see what else is setting up interestingly, this is a good moment to scan 33 healthcare AI stocks

With Revvity trading at $96.79 alongside analyst targets and intrinsic value estimates that suggest a discount, the key question is whether this is a genuine gap in pricing or if markets are already assuming stronger growth ahead?

Most Popular Narrative: 19% Undervalued

Revvity’s most followed narrative pegs fair value at $119.56, compared with the recent $96.79 close. This frames a sizeable discount that hinges on stronger long term earnings power.

Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Curious what kind of revenue trajectory and margin lift analysts are baking in to reach that fair value and support a richer future earnings multiple? The narrative leans heavily on recurring software, diagnostics strength and improving profitability assumptions that are very different from Revvity’s recent track record. It ties these assumptions to a specific earnings path and valuation multiple that readers may want to scrutinize in full.

Result: Fair Value of $119.56 (UNDERVALUED)

However, there are still real swing factors, including pressure from regulatory and reimbursement changes in China, as well as any prolonged softness in academic or government funding.

Another Lens On Valuation

The SWS DCF model points to a fair value of $137.65. At $96.79 the stock screens as undervalued on future cash flows, even though the current P/E of 45.2x sits well above the industry at 33.8x and a fair ratio of 20.9x. Which signal do you trust more?

Next Steps

Taking all of this in, does Revvity look more like an opportunity or a risk to you right now? Move quickly, review the underlying data, and let the numbers guide your view with 2 key rewards and 1 important warning sign

Looking for more investment ideas?

Before you move on, take a moment to line up a few fresh ideas so you are not relying on a single stock to carry your portfolio.

• Target stronger balance sheets by scanning companies in the solid balance sheet and fundamentals stocks screener (45 results) that pair financial resilience with room for future growth.
• Hunt for potential bargains by reviewing the 47 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
• Prioritise stability and income by checking out the 9 dividend fortresses that focus on higher yielding stocks with the potential for more consistent cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.